Goldman Sachs
SEEL

Goldman Sachs’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Goldman Sachs’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5
Closed -$24K – 5933
2023
Q2 		$24K Hold
5
– – ﹤0.01% 5532
2023
Q1 		$14.1K Hold
5
– – ﹤0.01% 5704
2022
Q4 		$14.3K Sell
5
-1
-17% -$3.49K ﹤0.01% 5729
2022
Q3 		$25K Sell
6
-33
-85% -$130K ﹤0.01% 5901
2022
Q2 		$103K Buy
39
+5
+15% +$13K ﹤0.01% 5857
2022
Q1 		$110K Sell
34
-7
-17% -$30.1K ﹤0.01% 6079
2021
Q4 		$255K Buy
41
+16
+64% +$123K ﹤0.01% 5755
2021
Q3 		$235K Sell
25
-20
-44% -$172K ﹤0.01% 5640
2021
Q2 		$453K Sell
45
-12
-21% -$197K ﹤0.01% 5285
2021
Q1 		$1.09M Buy
57
+41
+256% +$478K ﹤0.01% 4542
2020
Q4 		$99K Buy
+16
New +$62.8K ﹤0.01% 5293
2016
Q1 		– Hold
0
– -$15K – 7365
2015
Q4 		– Hold
0
– – – 6908
2015
Q3 		– Hold
0
– -$59K – 7528
2015
Q2 		– Hold
0
– – – 6824
2014
Q2 		– Hold
0
– -$28K – 7175
2014
Q1 		– Hold
0
– – – 6657

Other funds holding SEEL

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Goldman Sachs's SEEL Position: Q3 2023 in Review

Goldman Sachs sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2023, closing a stake of 5 shares — an estimated $24K sold.

Goldman Sachs first reported a position in SEEL in Q4 2020 and held it in 11 quarters. The position peaked at $1.09M in Q1 2021. 67 funds tracked by Wall St. Rank hold SEEL as of Q3 2023.

  • Goldman Sachs reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Goldman Sachs sold 5 Seelos Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $24K.
  • Goldman Sachs first reported a position in Seelos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
  • Goldman Sachs's Seelos Therapeutics, Inc. Common Stock position peaked at $1.09M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Goldman Sachs's 13F filing for Q3 2023, filed 14 Nov 2023.